EUVIMEDEUVIMED entdecken
Crossref

Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies

Kazumasa Oya iD, Yoshiyuki Nakamura iD, Larina Tzu-Wei Shen iD, Shoichiro Ishizuki, Satoshi Matsusaka, Yasuhiro Fujisawa iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Kazumasa Oya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. Hauptthemen laut MEDLINE: Melanoma, B7-H1 Antigen, Immune Checkpoint Inhibitors, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) bring prognostic benefits to patients with malignancies. However, there is a substantial number of patients whose lesions are not improved by ICIs. In addition, ICIs may cause immune‐related adverse events (irAEs), which could lead to an unfavorable prognosis with fatal consequences. Therefore, we conducted a retrospective study to evaluate the utility of circulating sPD‐L1 (soluble programmed cell death 1 ligand 1) as a biomarker in patients with advanced melanoma treated with anti–PD‐1 (programmed cell death 1 protein) antibodies. Sera from 31 consecutive patients were prospectively collected before and after anti–PD‐1 antibody treatment and the serum level of sPD‐L1 was evaluated. We found that high sPD‐L1 levels before treatment were associated with better prognosis, and this association was observed only in patients with a low tumor burden. We also found that sPD‐L1 levels were elevated in patients who developed severe irAEs after treatment, and the patients with severe irAEs had significantly higher fluctuations in sPD‐L1 (delta sPD‐L1) than those without severe irAEs. Our study suggests that serum sPD‐L1 level is a useful biomarker to predict tumor response and irAE development in patients with advanced melanoma treated with anti–PD‐1 antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaB7-H1 AntigenImmune Checkpoint InhibitorsSkin NeoplasmsBiomarkers, TumorProgrammed Cell Death 1 ReceptorHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overPrognosisTreatment OutcomeTumor Burden

Stichwörter der Autor:innen

biomarkersimmune checkpoint inhibitorsimmune‐related adverse eventsmetastatic melanomasoluble PD‐L1

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanBiomarkers, TumorProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Department of Clinical Research and Regional Innovation, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Tsukuba Clinical Research and Development Organization, University of Tsukuba, Tsukuba, Japan.
  • Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.

ORCID-Profile: Kazumasa Oya, Yoshiyuki Nakamura, Larina Tzu-Wei Shen, Yasuhiro Fujisawa

Zitieren

APA

Oya, K., Nakamura, Y., Shen, L. T., Ishizuki, S., Matsusaka, S., & Fujisawa, Y. (2024). Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17183

Vancouver

Oya K, Nakamura Y, Shen LT, Ishizuki S, Matsusaka S, Fujisawa Y. Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17183

BibTeX
@article{Oya2024,
  author = {Oya, Kazumasa and Nakamura, Yoshiyuki and Shen, Larina Tzu-Wei and Ishizuki, Shoichiro and Matsusaka, Satoshi and Fujisawa, Yasuhiro},
  title = {Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17183}
}
Kostenlos starten →